US Patent Issued to Juno Therapeutics on Oct. 7 for "Cells expressing a chimeric receptor from a modified CD247 locus, related polynucleotides and methods" (Washington Inventors)

ALEXANDRIA, Va., Oct. 8 -- United States Patent no. 12,435,120, issued on Oct. 7, was assigned to Juno Therapeutics Inc. (Seattle).

"Cells expressing a chimeric receptor from a modified CD247 locus, related polynucleotides and methods" was invented by Stephen Michael Burleigh (Seattle) and Christopher Heath Nye (Seattle).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are engineered immune cells, e.g. T cells, expressing a chimeric receptor comprising an intracellular region comprising a CD3zeta (CD3Zeta) signaling domain. In some embodiments, the engineered immune cells contain a modified CD247 locus that encodes the chimeric receptor or a portion thereof. In some embodiments, at least a porti...